L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables.
1. Clinical activity, tolerability and kinetic profile of L-sulpiride (200-300 mg/die p.o.) in relation to age, in 14 chronic schizophrenic in patients diagnosed according to DSM III-R, typed as negative forms, were studied. 2. The drug showed its efficacy in negative forms of schizophrenia, without any significant difference between negative and positive symptoms even if productive symptom scores were quite low already in pre-treatment condition. 3. No more side effects (anticholinergic and extrapyramidal) in elderly patients compared to young/adult ones were reported. 4. No significant differences between young/adult and elderly patients for the various pharmacokinetic parameters (t1/2, AUC, Cmax, Tmax, Vd and Cl), after acute and multiple dosing, were observed.
Mauri
M C
MC
Department of Clinical Psychiatry, University of Milan, Italy.
Leva
P
P
Coppola
M T
MT
Altamura
C A
CA
D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism / Q000523:psychology*; D001794:Blood Pressure / Q000187:drug effects; D004562:Electrocardiography; D005260:Female; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D013469:Sulpiride / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D013469:Sulpiride